Biomedical Engineering Reference
In-Depth Information
53. Scott, R.C., et al.: Targeting VEGF-encapsulated immunoliposomes to MI heart improves
vascularity and cardiac function. FASEB J 23(10), 3361-3367 (2009)
54. Silva,
E.A.,
Mooney,
D.J.:
Effects
of
VEGF
spatial
and
temporal
presentation
on
angiogenesis. Biomaterials 31(6), 1235-1241 (2010)
55. Kufe, D.W., et al.: Cancer Medicine. BC Decker, Hamilton (2003)
56. Hanahan, D., Weinberg, R.A.: Judah Folkman (1933-2008). Science 319(5866), 1055 (2008)
57. Eichhorn, M.E., et al.: Angiogenesis in cancer: molecular mechanisms, clinical impact.
Langenbecks Arch. Surg. 392(3), 371-379 (2007)
58. Kim, K.J., et al.: Inhibition of vascular endothelial growth factor induced angiogenesis
suppresses tumor growth in vivo. Nature 362(6423), 841-844 (1993)
59. Ferrara, N., et al.: Discovery and development of bevacizumab, an anti-VEGF antibody for
treating cancer. Nat. Rev. Drug. Discovery 3(5), 391-400 (2004)
60. Hurwitz, H., et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic
colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342 (2004)
61. Ferrara, N., Hillan, K.J., Novotny, W.: Bevacizumab (avastin), a humanized anti-VEGF
monoclonal antibody for cancer therapy. Biochem. Biophys. Res. Commun. 333(2), 328-335
(2005)
62. Escudier, B., et al.: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell
carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605), 2103-2111 (2007)
63. Escudier, B., et al.: Phase III trial of bevacizumab plus interferon alfa-2a in patients with
metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol.
28(13), 2144-2150 (2010)
64. Vredenburgh, J.J., et al.: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
J. Clin. Oncol. 25(30), 4722-4729 (2007)
65. Sandler, A., et al.: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung
cancer. N. Engl. J. Med. 355(24), 2542-2550 (2006)
66. Miller, K., et al.: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast
cancer. N. Engl. J. Med. 357(26), 2666-2676 (2007)
67. Van Cutsem, E., et al.: Phase III trial of bevacizumab in combination with gemcitabine and
erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol. 27(13), 2231-2237 (2009)
68. Kindler, H.L., et al.: Gemcitabine plus bevacizumab compared with gemcitabine plus placebo
in patients with advanced pancreatic cancer: phase III trial of the cancer and leukemia group
B (CALGB 80303). J. Clin. Oncol. 28(22), 3617-3622 (2010)
69. Ferrara, N.: Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth
Factor Rev. 21(1), 21-26 (2010)
70. Casanovas, O., et al.: Drug resistance by evasion of antiangiogenic targeting of VEGF
signaling in late-stage pancreatic islet tumors. Cancer Cell 8(4), 299-309 (2005)
71. Fisher, T., et al.: Mechanisms operative in the anti-tumor activity of temozolomide in
glioblastoma multiforme. Cancer J. 13(5), 335-344 (2007)
72. Paez-Ribas, M., et al.: Antiangiogenic therapy elicits malignant progression of tumors to
increased local invasion and distant metastasis. Cancer Cell 15(3), 220-231 (2009)
73. Norden, A.D., et al.: Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and
patterns of recurrence. Neurology 70(10), 779-787 (2008)
74. Chow, L.Q., Eckhardt, S.G.: Sunitinib: from rational design to clinical efficacy. J. Clin.
Oncol. 25(7), 884-896 (2007)
75. Motzer, R.J., et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
N. Engl. J. Med. 356(2), 115-124 (2007)
76. Demetri, G.D., et al.: Efficacy and safety of sunitinib in patients with advanced
gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
Lancet 368(9544), 1329-1338 (2006)
77. Goodman, V.L., et al.: Approval summary: sunitinib for the treatment of imatinib refractory
or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin. Cancer
Res. 13(5), 1367-1373 (2007)
Search WWH ::
Custom Search